Cognition Therapeutics Inc (CGTX): Shareholders' Equity
$34.27M
As of 2025-12-31
$33.02M
As of 2026-06-30
-5.2%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.27M | +82.8% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $18.75M | -23.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $24.47M | -39.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $40.25M | -21.5% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $51.27M | n/m | 2023-03-23, Balance as of period end |
| 2020-12-31 | -$68.18M | n/a | 2022-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $34.27M | +82.8% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $33.29M | -35.8% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $5.59M | -78.2% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$12.17M | n/m |
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | -$2.52M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $45.39M | -45.3% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $18.75M | -69.4% |
| Elutia Inc. (ELUT) | 2025-12-31 | $27.67M | n/m |
Compare CGTX, PMCB, SNTI, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗